We applied our delivery strategy to a mousemodel of human hereditary tyrosinemia and show that the treatment generatedfumarylacetoacetate hydrolase (Fah)-positive hepatocytes by correcting thecausative Fah-splicing mutation. Here, FAH is linked to tyrosinemia.